Search Results
Search for other papers by Adam Hagg in
Google Scholar
PubMed
Search for other papers by Eliza O’Shea in
Google Scholar
PubMed
Search for other papers by Craig A Harrison in
Google Scholar
PubMed
Department of Physiology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Australia
Search for other papers by Kelly L Walton in
Google Scholar
PubMed
complex with the ActRIIA/B receptors which effectively disables intracellular SMAD activation ( Fig. 2A ). Activin A and activin B have also been reported to stimulate SMAD-independent signalling pathways involving p38 MAPK, ERK1/2 and JNK ( Bao et al
South Australian Adult Genetics Unit, Royal Adelaide Hospital, Adelaide, Australia
Adelaide Medical School, University of Adelaide, Adelaide, Australia
Search for other papers by Sunita M C De Sousa in
Google Scholar
PubMed
Garvan Institute of Medical Research, Sydney, NSW, Australia
St Vincent’s Clinical School, University of New South Wales, Sydney, NSW, Australia
Search for other papers by Nèle F Lenders in
Google Scholar
PubMed
St Vincent’s Clinical School, University of New South Wales, Sydney, NSW, Australia
Search for other papers by Lydia S Lamb in
Google Scholar
PubMed
Academy for Medical Education, Faculty of Medicine, the University of Queensland, Brisbane, Australia
Search for other papers by Warrick J Inder in
Google Scholar
PubMed
Garvan Institute of Medical Research, Sydney, NSW, Australia
St Vincent’s Clinical School, University of New South Wales, Sydney, NSW, Australia
Search for other papers by Ann McCormack in
Google Scholar
PubMed
. 2020 b ). EGFR is a transmembrane glycoprotein, the binding of which triggers downstream signalling via MAPK and P13K pathways. Increased EGFR expression has been associated with proliferation, angiogenesis, invasion, recurrence and transition of PAs